Danish biotech company hangs up its boots
In spite of funding from Novo A/S, among others, and a number of prominent business people on the board of directors, the Danish biotech company Inagen has been forced to call it quits.
BY BENJAMIN WERNER CHRISTENSEN
Inagen could not hang on any longer; after having been on the prowl for cash for some time, the Danish biotech company has seen no option but to cash in its chips.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
